Swedish Orphan Biovitrum AB (publ) (FRA:B6E)

Market Cap	10.78B
Revenue (ttm)	2.52B
Net Income (ttm)	1.18M
Shares Out	n/a
EPS (ttm)	0.00
PE Ratio	9,164.64
Forward PE	18.49
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	8
Open	30.14
Previous Close	30.62
Day's Range	30.14 - 30.14
52-Week Range	22.40 - 31.00
Beta	n/a
RSI	60.24
Earnings Date	Feb 5, 2026

About FRA:B6E

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocy...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1939
• Employees: 1,806
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: B6E

Financial Performance

In 2024, FRA:B6E's revenue was 26.03 billion, an increase of 17.65% compared to the previous year's 22.12 billion. Earnings were 3.89 billion, an increase of 61.27%.

Financial numbers in SEK